Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroLogic Promoting PhenoSense HIV Drug Susceptibility Test To Physicians

This article was originally published in The Gray Sheet

Executive Summary

Sales reps from ViroLogic, Inc. began calling physicians across the U.S. on Nov. 15 to promote the company's recently commercialized phenotypic HIV drug susceptibility assay, PhenoSense HIV.

You may also be interested in...



Gilead Sales Reps To Promote Virco HIV Resistance Test Services

Gilead Sciences will leverage its 60-rep U.S. sales force under a collaborative promotional and educational effort with Virco to increase awareness among physicians treating patients with HIV of Virco's phenotypic and genotypic HIV resistance monitoring assays, the firms announced March 7.

Gilead Sales Reps To Promote Virco HIV Resistance Test Services

Gilead Sciences will leverage its 60-rep U.S. sales force under a collaborative promotional and educational effort with Virco to increase awareness among physicians treating patients with HIV of Virco's phenotypic and genotypic HIV resistance monitoring assays, the firms announced March 7.

ViroLogic, Inc.

Proposed initial public offering valued at up to $75 mil. is outlined in a preliminary prospectus filed Feb. 22 with the Securities and Exchange Commission. The South San Francisco biotechnology firm's first product, the PhenoSense HIV phenotypic test to directly and quantitatively measure resistance of a patient's HIV to antiviral drugs in order to facilitate appropriate drug selection, commenced active marketing in November 1999 (1"The Gray Sheet" Nov. 22, p. 15). The company is also developing PhenoSense products for other viral diseases, including hepatitis B and C. Proceeds from the IPO will be used to expand sales and marketing activities and for various capital expenditures, including clinical laboratory expansion. CIBC World Markets Corp. is lead manager of the offering; ING Barings and Prudential Vector Healthcare Group are co-managers

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel